1. Scrip
  2. >>COVID-19

InflaRx Picks Outcomes-Based Reimbursement For COVID-19 Drug

 
• By Alaric DeArment

The model, more common with high-cost gene therapies, is designed to de-risk use of the drug for hospitals in the event that patients with COVID-19-related ARDS do not survive.

• Source: Shutterstock

InflaRx N.V. is looking to expand the availability of Gohibic (vilobelimab) for certain hospitalized COVID-19 patients under its US Food and Drug Administration emergency use authorization (EUA) by using the sort of reimbursement method more commonly associated with high-cost outpatient treatments like gene therapies.

Scrip spoke with executives from the company to discuss how it plans to apply the

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from COVID-19

More from Scrip

AbbVie On MFN: ‘We Have To Take It Seriously’

 
• By Jessica Merrill

AbbVie chief commercial officer Jeffrey Stewart called Trump’s drug pricing plan a “disruption” but said ultimately the delta between US and EU drug prices may not be as high as some expect.

Industry Leaders Grapple With Trump’s MFN Pricing Plan

 
• By Jessica Merrill

At the Bank of America health care conference, pharma leaders speculated on what Trump’s executive order on drug pricing could mean for US and European drug prices.

GSK Pays $1.2bn For Phase III-Ready MASH Contender

 
• By Andrew McConaghie

The acquisition of Boston Pharma’s once-a-month FGF21 analog adds to GSK’s liver disease portfolio.